المؤلفون: Janin M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Ortiz-Barahona V; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., de Moura MC; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Martínez-Cardús A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Llinàs-Arias P; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Soler M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Nachmani D; Department of Medicine and Pathology, Cancer Research Institute, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Pelletier J; Molecular Mechanisms and Experimental Therapy in Oncology Program, Metabolism and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Schumann U; EMBL-Australia Collaborating Group, Department of Genome Sciences, The John Curtin School of Medical Research, The Australian National University, Garran Road, Acton, ACT, 2601, Australia., Calleja-Cervantes ME; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Moran S; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Guil S; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Bueno-Costa A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Piñeyro D; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Perez-Salvia M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Rosselló-Tortella M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Piqué L; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Bech-Serra JJ; Proteomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., De La Torre C; Proteomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain., Vidal A; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain., Martínez-Iniesta M; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain., Martín-Tejera JF; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain., Villanueva A; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain., Arias A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain., Cuartas I; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain., Aransay AM; Centro de Investigación Bimédica en Red de Enfermedades hepáticas y Digestivas (CIBERehd), CIC bioGUNE, 801A Bizkaia Technology Park, 48160, Derio, Spain., La Madrid AM; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.; Pediatric Neuro-Oncology Unit, Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain., Carcaboso AM; Preclinical Therapeutics and Drug Delivery Research Program, Fundacio Sant Joan de Deu, Barcelona, Catalonia, Spain., Santa-Maria V; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.; Pediatric Neuro-Oncology Unit, Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain., Mora J; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain., Fernandez AF; Institute of Oncology of Asturias (IUOPA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), 33011, Oviedo, Spain., Fraga MF; Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Universidad de Oviedo-Principado de Asturias, Oviedo, Spain., Aldecoa I; Pathology-Brain Bank, Hospital Clínic de Barcelona-CDB-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain., Pedrosa L; Glioma and Neural Stem Cell Group and Translational Genomics and Targeted Therapeutics in Solid Tumors Team, IDIBAPS, Barcelona, Catalonia, Spain., Graus F; Clinical and Experimental Neuroimmunology, IDIBAPS, Barcelona, Catalonia, Spain., Vidal N; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain., Martínez-Soler F; Faculty of Medicine and Health Sciences-Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain., Tortosa A; Faculty of Medicine and Health Sciences-Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain., Carrato C; Department of Pathology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain., Balañá C; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, 08916, Badalona, Barcelona, Catalonia, Spain., Boudreau MW; Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA., Hergenrother PJ; Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA., Kötter P; Institute for Molecular Biosciences, Goethe University, Frankfurt, Germany., Entian KD; Institute for Molecular Biosciences, Goethe University, Frankfurt, Germany., Hench J; Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, 4031, Basel, Switzerland., Frank S; Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, 4031, Basel, Switzerland., Mansouri S; Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada., Zadeh G; Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada., Dans PD; Joint IRB-BSC Program on Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028, Barcelona, Catalonia, Spain., Orozco M; Joint IRB-BSC Program on Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028, Barcelona, Catalonia, Spain.; Department of Biochemistry and Biomedicine, University of Barcelona, 08028, Barcelona, Spain., Thomas G; Molecular Mechanisms and Experimental Therapy in Oncology Program, Metabolism and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.; Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati Medical School, Cincinnati, OH, 45267-0508, USA., Blanco S; CIC bioGUNE, 801A Bizkaia Technology Park, 48160, Derio, Spain.; Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), University of Salamanca, 37007, Salamanca, Spain., Seoane J; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain., Preiss T; EMBL-Australia Collaborating Group, Department of Genome Sciences, The John Curtin School of Medical Research, The Australian National University, Garran Road, Acton, ACT, 2601, Australia.; Victor Chang Cardiac Research Institute, Darlinghurst (Sydney), NSW, 2010, Australia., Pandolfi PP; Department of Medicine and Pathology, Cancer Research Institute, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Esteller M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. mesteller@carrerasresearch.org.; Department of Biochemistry and Biomedicine, University of Barcelona, 08028, Barcelona, Spain. mesteller@carrerasresearch.org.; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.; Josep Carreras Leukaemia Research Institute (IJC), Ctra de Can Ruti, Camí de les Escoles s/n, 08916, Badalona, Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.

المصدر: Acta neuropathologica [Acta Neuropathol] 2019 Dec; Vol. 138 (6), pp. 1053-1074. Date of Electronic Publication: 2019 Aug 19.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0412041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0533 (Electronic) Linking ISSN: 00016322 NLM ISO Abbreviation: Acta Neuropathol Subsets: MEDLINE

مواضيع طبية MeSH: Epigenesis, Genetic*, Brain Neoplasms/*metabolism , Glioma/*metabolism , Methyltransferases/*metabolism , Muscle Proteins/*metabolism , Protein Biosynthesis/*physiology , Ribosomes/*metabolism, Animals ; Biomarkers, Tumor ; Cell Line, Tumor ; DNA Methylation ; Humans ; Methyltransferases/genetics ; Mice, Nude ; Muscle Proteins/genetics ; Neoplasm Transplantation ; RNA, Ribosomal, 28S

المؤلفون: Schlein, Lisa J, Fadl-Alla, Bahaa, Pondenis, Holly C, Lezmi, Stéphane, Eberhart, Charles G, LeBlanc, Amy K, Dickinson, Peter J, Hergenrother, Paul J, Fan, Timothy M

المصدر: Frontiers in Oncology. 9(FEB)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Brain Cancer, Brain Disorders, Orphan Drug, Cancer, Neurosciences, glioma, meningioma, brain cancer, procaspase-3, PAC-1, canine comparative, Clinical sciences, Oncology and carcinogenesis

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/9vb6d2tc